Country/

Institution

Start of vaccination (year)

Target audience and dosage

Vaccine offered

WHO

2007 (recommendation)

♀: 9 to 14 years (single dose or 2 doses);

♀: 15 to 20 years of age (single dose or 2 doses);

♀: >21 years (2 doses);

6-month interval between doses.

2-Valent

4-Valent

9-Valent

South Africa

2014

9 to 14 years (2 doses);

Vaccination site: schools.

2-Valent

Argentina

2011

♀♂: >10 years (1 dose or 2 doses, 6-month interval between doses);

Not informed

Australia

2007

♀♂: <15 years (2 doses, 6-month interval between doses);

♀♂: ≥15 years (3 doses, 2- and 6-month interval between doses).

9-Valent

Brazil

2014

♀♂: 9 to 14 years (2 doses);

Vaccination site: basic health units.

4-Valent

Canada

2006

♀: 9 to 45 years (2 or 3 doses, 3 to 6 months interval between doses);

♂: 9 to 26 years (2 or 3 doses, 3 to 6 months interval between doses);

Vaccination site: schools.

2-Valent

4-Valent

9-Valent

South Korea

2011

♀: 9 to 45 years (3 doses);

♂: 9 to 25 years¹ and 26 years² (3 doses).

2-Valent¹

4-Valent²

9-Valent²

United States

2011

♀♂: 9 to 14 years (2 doses, 6 to 12 months interval between doses);

♀♂: 15 to 26 years (3 doses, 2- and 6-month interval between doses);

9-Valent

Malaysia

Not informed

13 to 14 years;

Not informed

European Union

2006-2018

♀♂: 9 to 14 years (2 doses, 6 to 12 months interval between doses);

♀♂: >15 years (3 doses);

Vaccination site: schools.

2-Valent

4-Valent

9-Valent